APP and Alzheimer disease: In particular, we observed that senile plaque (SP) burden was significantly reduced in STZ-treated APP/PS1 (T1D-AD) and in APP/PS1xdb/db (T2D-AD) mice compared to APP/PS1 mice [F(3,21) = 11.81, **p < 0.01 vs. APP/PS1-STZ and APP/PS1xdb/db] (Additional file 1: Figure S1B).